Introduction: The diagnosis of tuberculous pleural effusions (TBPE) has some limitations. Objective: To evaluate the efficacy of Interleukin-27 (IL-27) in the diagnosis of TBPE. Methods: A total of 431 pleural effusions were classified as tuberculous (n=70), neoplastic (n=146), parapneumonic (n=58), empyemas (n=28), miscellaneous (n=41), and transudates (n=88). IL-27, adenosine deaminase (ADA), ADA-2, interferon-gamma (IFNγ) and the ADA·IL-27 and ADA-2·IL-27 products were measured in all of the fluids. The diagnostic yield of IL-27 was evaluated using operating characteristics (ROC) analysis. Results: With a cut-off point of 0.55 ng/mL, IL-27 had a sensitivity of 91.4% and a specificity of 85.1%, which were significantly less than the rest of the parameters. The area under the ROC curve (0.963) was also significantly less than the rest of the markers, except for IFNγ. However, IL-27 improves the sensitivity of the ADA and ADA-2 through ADA·IL-27 and ADA-2·IL-27 products (100% for both). Conclusions: IL-27 is less efficient than ADA and ADA-2 in the diagnosis of TBPE. However, using the products of ADA·IL-27 and ADA-2·IL-27, helps to improve the diagnostic sensitivity of ADA and ADA-2, thus it could be useful in situations of high clinical suspicion and low levels of ADA. A value above the cut-off point of the latter is practically diagnostic of TBPE.
Introduction: The characteristics and clinical relevance of pleural effusion (PLEF) in acute pulmonary embolism (APE) are not fully understood. Methods: A single-centre, retrospective study was performed of patients admitted with APE classified according to the subsequent development or not of PLEF. A model was built to predict PLEF and its impact on 30-day all-cause mortality was investigated. Results: A total of 1602 patients with APE were included (median age, 74 (61, 82) years; 674 men (42.1%); 382 (23.8%) with PLEF). PLEF was associated with a higher number of comorbidities (p=0.015); more peripheral APE (0.001); a higher frequency of pulmonary infarctions (p<0.001) and higher 30-day all-cause mortality (p=0.004) compared with those without PLEF. Bilateral PLEFs, as compared with unilateral, were associated with a higher number of comorbidities (p=0.009); more severe (simplified Pulmonary Embolism Severity Index ≥1; p<0.001) and higher 30-day all-cause mortality (p<0.001). On multivariate analysis, the presence of PLEF was associated with atrial fibrillation (OR 2.00; 95% CI 1.32 to 3.02), congestive heart failure (OR 3.00; 95% CI 1.81 to 5.00), pulmonary infarction (OR 3.19; 95% CI 2.38 to 4.29) and a Charlson index ≥3 (OR 1.59; 95% CI 1.03 to 2.45). The predictive model for PLEF had a moderate power of discrimination (area under the curve, AUC 0.76; 95% CI 0.73 to 0.79), whereas the predictive model for mortality showed a good predictive power (AUC 0.89; 95% CI 0.86 to 0.93). The presence of PLEF doubles the probability of death (OR 2.02; 95% CI 1.11 to 3.68). When PLEF is bilateral, the probability of death is four times higher, as compared with unilateral PLEF (OR 4.07; 95% CI 1.53 to 10.85; AUC 0.90; 95% CI 0.84 to 0.95). Conclusions: A significant number of APE patients develop PLEF. The model showed a good power of discrimination for the prediction of mortality. The probability of death from APE doubles in the presence of PLEF. Patients with APE and concomitant bilateral PLEF have a fourfold higher risk of mortality, as compared with patients with concomitant unilateral PLEF.